Rx Communications Group, LLCCapabilities Overview

2000 – 2014: Providing award-winning communications counsel to life sciences and health care companies

ABOUT Rx COMMUNICATIONS

Specialists in the life science and health care industries

Partner-driven -- Senior level counsel on EVERY account

Navigate clients through up and down market cycles, various political health care agendas and technology trends

ABOUT Rx COMMUNICATIONS

Experience with private and public companies – domestic and international

Focused on what we do best: Investor Relations and Financial/Science Media Relations

Strong Wall Street and media contacts

Headquartered in New York City

PRIVATE COMPANIES

Services for Private Companies

WHY EMBARK ON AN IR/PR PROGRAM AS A PRIVATE COMPANY? Lay the groundwork for future

financings and eventual IPO

Assist with partnering activities by building corporate awareness

Build awareness of disease indications to generate product interest

Align company with reputable bankers

Become accustomed to working within disclosure rules i.e., Reg. FD

PROVIDING VALUE TO PRIVATE COMPANIES

Develop key messages positioned for analysts and investors

Develop collateral materials to tell story integrating key messages

Target and facilitate introductions to venture capitalists and institutional investors

Target and advise on corporate finance team

Target and facilitate introductions to sell-side analysts

PROVIDING VALUE TO PRIVATE COMPANIES

Build presence on the web

Review upcoming newsworthy events and develop story ideas for the media

Cultivate reporter interest

Introduce to conference circuit

Strategically position company news to optimize impact

Develop company disclosure policy

ACTIVITIES SUROUNDING IPO

Assist in the selection of banking team – beginning of quiet period

Press release announcing registration for offering

Develop roadshow presentation

Supplement banker’s list of target institutions

Presentation training

ACTIVITIES SURROUNDING IPO

“Teach-ins” at banks

Roadshow

Press release announcing completion of IPO

“Welcome letter” to new shareholders

Create disclosure policy

Quiet period compliance

PUBLIC COMPANIES

Services for Public Companies

AFTER-MARKET SUPPORT

Need for continual dialogue with shareholders

Ongoing targeting of investors for future financings

Increase analyst coverage beyond banking support

Fulfill disclosure requirements

Crisis communications

Strategic media outreach

GETTING STARTED: FIRST STEPS

Strategy session in order to immerse ourselves in corporate story

Define key message points

Understand perceptions existent in the marketplace

Create targeted list of sell-side analysts, venture capitalists and fund managers

GETTING STARTED: FIRST STEPS

Review collateral materials

Create VIP blast e-mail/fax lists

Develop media lists

Design action plan

Rx COMMUNICATIONS CAPABILITIES

Strategic Counsel Roadshows Analyst Contact Investor Targeting Investment and Industry Conferences Follow-up and Analysis to Key Events Press Release Writing News Conferences/Press Briefings Video/Radio News Releases Fact Sheets Annual Reports

Rx COMMUNICATIONS CAPABILITIES

Crisis Communications Mergers and Acquisitions Positioning Strategy Perception Audits Conference Calls Presentation Training Placement Strategy Financial, Trade and Local Media

Contacts Slide Presentations Web Site Development

THE Rx TEAM

Melody A. Carey, Co-President

Founded Rx Communications in 2000

Head of Corporate Communications and Spokesperson, Schein Pharmaceutical, Inc.

Director of Investor Relations, The Multicare Companies, Inc.

Executive, Noonan/Russo Communications

Former health care/life sciences investment banker, Kidder, Peabody & Co.

THE Rx TEAM

Rhonda Chiger, Co-President

Founded Rx Communications in 2000

Senior Managing Director, Global Consulting Practice, Thomson Financial

Managed Life Sciences departments for Noonan/Russo and Dewe Rogerson

Established London office for health care investor relations firm

Manager, Investor Relations, American Stock Exchange

THE Rx TEAM

Eric Goldman, Vice President

Six years with Rx Communications

25 years experience in public relations and as a media relations strategist specializing in biotechnology, health care, technology and consumer products

Senior Director and Vice President at GlobalFluency

Handled media relations at Spector & Associates and Brouillard Communications, a division of J. Walter Thompson

Earned 2 Silver Anvil awards for public relations excellence

THE Rx TEAM

Paula B. Schwartz, Senior Vice President

Ten years with Rx Communications

Partner, FRB/Weber Shandwick, oldest and largest Investor Relations firm in the U.S.

Vice President, ECOM Consultants, Inc., an investor relations firm

Vice President/Director of Investor Relations Programs, KCS&A Public Relations, a public relations and investor relations consultancy

Rx COMMUNICATIONS CURRENT CLIENT LIST ActoGeniX NV (Private)

Alexandria Real Estate Equities, Inc. (NYSE: ARE)

Alexion Pharmaceuticals Inc. (Nasdaq: ALXN)

Bio-Path Holdings, Inc. (Nasdaq: BPTH)

Ikaria, Inc. (Private)

InnoPharma, Inc. (Private)

Intact Medical Corporation (Private)

MAXIMUS, Inc. (NYSE: MMS)

MolMed S.p.A. (Milan: MLM)

Rx COMMUNICATIONS CURRENT CLIENT LIST

Nanotherapeutics, Inc. (Private)

Neurotrope, Inc. (OTCQB: NTRP)

Ophthotech Corporation (Nasdaq: OPHT)

Oxford BioMedica plc (LSE: OXB)

Orexo AB (OTCQX: ORXOY)

PharmAthene, Inc. (NYSE MKT: PIP)

Photocure (OSE: PHO)

Sigma-Tau Pharmaceuticals, Inc. (Private)

StemBioSys Inc. (Private)

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL)

OURx SUCCESSES

Helped to grow Alexion Pharmaceuticals’ institutional shareholder base from 30% in 1996 to approximately 95% today.

Launched not-for-profit Immune Tolerance Institute resulting in broad coverage in the U.S. including CBS Radio Network, San Francisco Business Times and Drug Discovery News.

Garnered coverage for Catalyst Pharmaceutical Partners’ compound for cocaine addiction. Placements included cover stories in Newsweek, Scientific American Mind and NeuroInvestment.

OURx SUCCESSES

Designed and implemented assertive investor outreach program for PDI which doubled trading volume and tripled its stock price within nine months.

Arranged feature coverage focused on Hodgkins and non-Hodgkins lymphoma for MethylGene with Genetic Engineering News, Pink Sheet, BioCentury and Pharmawire

Implemented aggressive IR program for PharmAthene, Inc. which enabled the company to obtain coverage from two new sell-side analysts, garner investments from four new institutional funds and increase trading volume by three-fold within nine months.

OURx SUCCESSES

Generated feature articles with Dow Jones Newswire, BioWorld Today, FierceBiotech for the TetraLogic Pharmaceuticals Series C financing.

Devised communications campaign to increase visibility of Amorcyte’s enriched bone marrow stem cell therapy by maximizing clinical data presented at American College of Cardiology (ACC) conference. Leveraged key opinion leaders who presented Amorcyte’s data to gain media coverage, surpassing competitors with later stage clinical data and larger operating budgets. News coverage included: Reuters, CBS Radio Network, Start-Up Magazine & Pharmawire.

OURx SUCCESSES

Generated news coverage with Dow Jones Newswire, Wall Street Journal.com, Drug Discovery & Development for launch of Neovacs autoimmune disease therapeutics.

Developed compelling key messages and arranged media interviews surrounding ZIOPHARM Oncology sarcoma clinical trials resulting in news coverage from Bloomberg Television, Reuters Newswire, BusinessWeek, Associated Press, Wall Street Journal and Forbes.

Within nine months, re-positioned MAXIMUS from a business processing company to a health care services company. Garnered health care sell-side research coverage from Bank of America and Citigroup Global Markets.

OURx SUCCESSES

We are pleased to announce that RxCommunications has been selected by PR Week

as a finalist forBoutique PR Agency of the Year

Rx Communications was named Best Small PR Agency

by League of American Communications Professionals

Rx Communications Group was honored with theStevie Award for Best Investor Relations

Program for work on behalf of specialty

pharmaceutical company, NexMed, Inc.

OURx SUCCESSES

Rx Communications was honored with the SABREAwards Certificate of Excellence for Building a North

American Investor Base for client Syngenta AG.

We are also pleased to share that our work for ImpactRx has won an Honorable Mention

Award in LACP’s (League of AmericanCommunications Professionals) Publicity

Campaign Competition.

Rx Communications received an honorable MentionAward from PR News, as part of the PR News Platinum PR

Awards. The award was issued in theFinancial/Investor Relations category, for the company's

work on behalf of Genaissance Pharmaceuticals, Inc.

WHY Rx COMMUNICATIONS?

Specialist industry knowledge and expertise

Personal attention from Rx partners

Decades of experience in strategic counsel and implementation of financial public relations programs

Unique niche in working with private companies

Well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions

“The Street” knows and trusts us

For Additional Information:Rx Communications Group, LLC

555 Park Avenue5th Floor

New York, NY 10022(917) 322-2568www.RxIR.com